.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,580,830

« Back to Dashboard

Claims for Patent: 8,580,830

Title:Non-mucoadhesive film dosage forms
Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.
Inventor(s): Leichs; Christian (Alfdorf, DE), Breitenbach; Armin (Leverkusen, DE), Lehrke; Ingo (Cologne, DE), Galfetti; Paolo (Comasco, IT)
Assignee: Labtec GmbH (DE) APR Applied Pharma Research S.A. (CH)
Application Number:12/443,414
Patent Claims: 1. A non-mucoadhesive orally disintegrating film, able to disintegrate upon contact with saliva in the buccal cavity within about sixty seconds, comprising ondansetron or a pharmaceutically acceptable salt thereof in combination with a hydrophilic binder and a water-soluble diluent, wherein: a) said film comprises from about 4 to 24 mg ondansetron or a pharmaceutically acceptable salt thereof; b) said ondansetron or pharmaceutically acceptable salt thereof is present in an amount of from about 0.05% to about 50% (w/w/), based on the total weight of the film; c) said film has a Tmax of from about 1.0 to about 2.5 hours; d) said ondansetron or pharmaceutically acceptable salt thereof has an absolute bioavailability in said film of about 45-75%; and e) wherein the said film further comprises means for retarding absorption of active ingredient through the oral mucosa wherein the means for retarding the absorption of active ingredient through the oral mucosa are selected from the group consisting of: (1) an ion exchange resin that binds ondansetron and prevents its ionization and dissolution upon disintegration of the film, wherein said ion exchange resin is selected from the group consisting of polymers and copolymers of acrylic acid, methacrylic acid, sulfonated styrene, sulfonated divinylbenzene, dextrans, and silica gel modified by the addition of ionic groups; (2) pH adjusting agents; (3) cyclodextrin or acrylate polymers; and (4) ondansetron in base form; wherein said retarding means are able to deliver greater than 60% of said ondansetron to the gastrointestinal tract when the film is placed on the tongue, allowed to disintegrate and subsequently swallowed.

2. The non-mucoadhesive orally disintegrating film of claim 1, wherein said retarding means are able to deliver greater than 70% of said ondansetron to the gastrointestinal tract when the film is placed on the tongue, allowed to disintegrate, and subsequently swallowed.

3. The non-mucoadhesive orally disintegrating film of claim 1, wherein said retarding means are able to deliver greater than 80% of said ondansetron to the gastrointestinal tract when the film is placed on the tongue, allowed to disintegrate, and subsequently swallowed.

4. The non-mucoadhesive orally disintegrating film of claim 1, wherein said retarding means are able to deliver greater than 90% of said ondansetron to the gastrointestinal tract when the film is placed on the tongue, allowed to disintegrate, and subsequently swallowed.

5. The non-mucoadhesive orally disintegrating film of claim 1, wherein said retarding means are able to deliver greater than 95% of said ondansetron to the gastrointestinal tract when the film is placed on the tongue, allowed to disintegrate, and subsequently swallowed.

6. The non-mucoadhesive orally disintegrating film of claim 1, wherein the ondansetron comprises Form B ondansetron.

7. The non-mucoadhesive orally disintegrating film of claim 1, comprising either 4 mg or 8 mg of ondansetron.

8. The non-mucoadhesive orally disintegrating film of claim 1, wherein the film is a single layer homogenous film, having a weight from about 40 to about 120 milligrams, a thickness of from 10 to 200 microns, and a surface area of less than 7 cm.sup.2.

9. The non-mucoadhesive orally disintegrating film of claim 1, wherein the film comprises ondansetron, polyvinylalcohol, polyethylene glycol, glycerol anhydrous, rice starch, acesulfam K, titanium dioxide, menthol and polysorbate.

10. The non-mucoadhesive orally disintegrating film of claim 1, wherein the film comprises 8.0 mg ondansetron, 22.0 mg polyvinylalcohol, 6.0 mg polyethylene glycol, 2.0 mg glycerol anhydrous, 10.0 mg rice starch, 0.2 mg acesulfam K, 0.3 tug titanium dioxide, 1.0 mg menthol, and 1.0 mg polysorbate.

11. The non-mucoadhesive orally disintegrating film of claim 1 for use in the treatment or prevention of emesis.

12. A non-mucoadhesive orally disintegrating film, able to disintegrate upon contact with saliva in the buccal cavity within about 60 seconds, comprising ondansetron in combination with a hydrophilic binder and a water soluble diluent, wherein: a) said film comprises about 4 or about 8 mg ondansetron in the form of a free base; b) said ondansetron is present in an amount of from about 0.05% to about 50% (w/w), based on the total weight of the film; and c) said film has a Tmax of from about 1.0 to about 2.5 hours; d) said ondansetron has an absolute bioavailability in said film of about 45-75%; and e) wherein said film comprises means for retarding absorption of active ingredient through the oral mucosa wherein the means for retarding the absorption of active ingredient through the oral mucosa are selected from the group consisting of: (1) an ion exchange resin that binds ondansetron and prevents its ionization and dissolution upon disintegration of the film, wherein said ion exchange resin is selected from the group consisting of polymers and copolymers of acrylic acid, methacrylic acid, sulfonated styrene, sulfonated divinylbenzene, dextrans, and silica gel modified by the addition of ionic groups; (2) pH adjusting agents; (3) cyclodextrin or acrylate polymers; and (4) ondansetron in base form; wherein said retarding means are able to deliver greater than 60% of said ondansetron to the gastrointestinal tract when the film is placed on the tongue, allowed to disintegrate, and subsequently swallowed.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc